,for, Item ID-
  • #1184533
  • Glaxo Specialty (Medical Benefit) #00173088101

NUCALA® Mepolizumab 100 mg Injection

NUCALA, SDV 100MG

Features

  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: Add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non hematologic secondary cause.
  • More …
Container Type
Prefilled Auto-Injector Prefilled Syringe Single-Dose Vial
Strength
100 mg 100 mg / mL
  Log In to Order
or

Product Specifications


Features
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: Add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
  • NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non hematologic secondary cause.
  • Requires Refrigeration

Professionals Also Viewed